Metadata record for the manuscript: Phenotypic discordance between primary and metastatic breast cancer in the large scale real-life multicenter French ESME cohort
Creators: name: Grinda, Thomas
name: Joyon, Natacha
name: Lusque, Amélie
name: Lefèvre, Sarah
name: Arnould, Laurent
name: Penault-Llorca, Frédérique
name: Macgrogan, Gaëtan
name: Treilleux, Isabelle
name: Vincent-Salomon, Anne
name: Haudebourg, Juliette
name: Maran-Gonzalez, Aurélie
name: Charafe-Jauffret, Emmanuelle
name: Courtinard, Coralie
name: Franchet, Camille
name: Verriele, Véronique
name: Brain, Etienne
name: Tas, Patrick
name: Blanc-Fournier, Cécile
name: Leroux, Agnès
name: Loussouarn, Delphine
name: Berghian, Anca
name: Brabencova, Eva
name: Ghnassia, Jean Pierre
name: JeanYves Scoazec
name: Delaloge, Suzette
name: Filleron, Thomas
name: Lacroix-Triki, Magali
Publisher: name: figshare
Year: 2021
Subjects: subject: 69999 Biological Sciences not elsewhere classified
subject: FOS: Biological sciences
subject: FOS: Biological sciences
subject: Cancer
subject: 111299 Oncology and Carcinogenesis not elsewhere classified
subject: FOS: Clinical medicine
subject: FOS: Clinical medicine
subject: Biomarkers
subject: 119999 Medical and Health Sciences not elsewhere classified
subject: FOS: Other medical sciences
subject: FOS: Other medical sciences

description: <b>Summary</b><br> This metadata record provides details of the data supporting the claims of the related manuscript: “Phenotypic discordance between primary and metastatic breast cancer in the large scale real-life multicenter French ESME cohort ”. The related study aimed to compare phenotypic profiles between matched primary and metastatic breast cancer (MBC) in the ESME database, a National real-life multi-centre cohort of MBC patients. Type of data: Data collected include patient and tumour characteristics at primary and metastatic settings, outcomes and treatment patterns. Subject of data: The ESME-MBC cohort is an ongoing national cohort collecting real-life information from all consecutive MBC patients aged &gt;18 years who initiated their MBC treatment in one of the 18 French Comprehensive Cancer Centers. Population characteristics: For the primary objective and the first secondary objectives of the present study, patients were eligible if they had at least one histological report with HR or HER2 status on primary tumour and at least one histological report with HR or HER2 status on a metastasis within the first 6 months of MBC diagnosis, before any disease progression (main study population). For the other secondary objective, patients were included if they had histological reports and HR or HER2 status on primary tumour and metastasis within 6 months from the first progression of MBC (second study population). Date of data collection: MBC patients who entered the cohort from 2008/01/01 to 2014/12/31 Trial registration number: https://clinicaltrials.gov/ct2/show/NCT03275311 <b>Data access</b> All data supporting the findings of the related study are contained in the ESME data base, which is managed by Unicancer (http://www.unicancer.fr/). However, the ESME data base is not publicly available for the following reason: In the ESME Research program, public data sharing is not automatic in order to ensure that only trained users can analyse the ESME datasets. The analysis datasets will be made available only under data transfer and use agreements executed between Unicancer, ICR (https://www.icr.ac.ukx/) and the potential licensee. Interested parties should contact the corresponding author. <b>Corresponding author(s) for this study</b> Dr Magali Lacroix-Triki, Department of Biopathology, Gustave Roussy, 114 rue Edouard Vaillant, Villejuif 94805, France. Tel: +33 1 42 11 44 55. Fax: +33 1 42 11 52 65. Email: magali.lacroix-triki@gustaveroussy.fr <br> <b>Study approval </b> The study was approved by an independent ethics committee (Comité De Protection Des Personnes Sud-Est II- 2015-79). No formal dedicated informed consent was required but all patients had approved the re-use of their electronically recorded data. In compliance with French regulations, the ESME MBC database was authorised by the French data protection authority (Registration ID 1704113; authorisation N°DE-2013.-117). Moreover, in compliance with the applicable European regulations, a complementary authorisation was obtained on 2019 regarding the ESME research Data Warehouse.